

DIRECTORS AND SENIOR MANAGEMENT

BOARD OF DIRECTORS

Our Board consists of nine Directors, comprising five executive Directors, one non-executive Director and three independent non-executive Directors. Pursuant to the Articles of Association, our Directors are elected and appointed by our Shareholders at a Shareholders’ meeting for a term of three years, which is renewable upon re-election and re-appointment. The following table sets forth the key information about our Directors as of the Latest Practicable Date.

Name	Age	Positions	Roles and responsibilities	Date of joining our Group	Date of appointment as a Director
Mr. Jiang Yun (江雲) ⁽¹⁾	63	Chairman of the Board and executive Director	Overseeing the management and strategic development of our Group	December 30, 2001	December 30, 2001
Mr. Feng Bin (馮斌)	62	Executive Director and general manager	Overall corporate and business strategies and key business and operational decision-making of our Group	May 10, 2003	May 10, 2009
Mr. Jiang Ercheng (江爾成) ⁽¹⁾	35	Executive Director	Overall strategic planning and development of our Group	February 22, 2019	February 22, 2019
Mr. Luo Yujin (羅玉金)	43	Executive Director and deputy general manager	Overall management of sales center of our Group	September 12, 2003	February 22, 2019
Mr. Lan Zelun (蘭澤倫)	43	Executive Director and secretary of the Board	Information disclosure and investor relations management, equity affairs management and corporate governance	July 3, 2007	February 25, 2025
Mr. Lai Zhitian (賴智填)	57	Non-executive Director	Overseeing Board affairs and giving strategic advice and guidance on the business operations of our Group	August 14, 2023	August 14, 2023
Dr. Wan Jianbo (萬建波)	45	Independent non-executive Director	Providing independent advice and judgment to our Board	October 7, 2023	October 7, 2023
Dr. Chen Jianping (陳建萍)	68	Independent non-executive Director	Providing independent advice and judgment to our Board	February 25, 2025	February 25, 2025
Ms. Liu Jianhua (劉建華)	56	Independent non-executive Director	Providing independent advice and judgment to our Board	March 26, 2025	March 26, 2025

Note:

(1) Mr. Jiang Yun is the father of Mr. Jiang Ercheng.

Executive Directors

Mr. Jiang Yun (江雲), aged 63, is the founder, chairman of the Board and an executive Director. Mr. Jiang was appointed as a Director and the chairman of the Board in December 2001 and was redesignated as an executive Director on March 26, 2025. He is primarily responsible for overseeing the management and strategic development of our Group.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Jiang’s journey in the pharmaceutical industry and TCM sector spans almost four decades, marked by notable leadership roles in several pharmaceutical and investment companies, including (i) as the chairman of the board of directors at Kinna Investment since April 1996; (ii) as the chairman of the board of directors at Chengdu Kinna United Pharmaceutical Co., Limited. (成都國嘉聯合製藥有限公司) from April 1996 to August 2007, as well as at its subsidiary, Sichuan Gulin Gansu Pharmaceutical Company Limited (四川古蘭肝蘇藥業有限公司), from June 2001 to August 2007; and (iii) as an executive director at Pharmesis International Ltd. (中嘉國際有限公司), a company founded by Mr. Jiang and listed on the Singapore Exchange (stock code: BFK) (“**Pharmesis International**”) from October 2004 to January 2009 and from January 2015 to December 2017.

Additionally, Mr. Jiang Yun has been the vice president of China Association of Traditional Chinese Medicine (中國中藥協會) since November 2019 and the president of Chengdu Chinese Herbal Medicine and Chinese Medicine Drinking Tablets Industry Association (成都市中藥材中藥飲片行業協會) since December 2016.

Mr. Jiang obtained a master’s degree in science from West China University of Medical Sciences (華西醫科大學) (currently known as the West China Medical Center of Sichuan University (四川大學華西醫學中心)) in China in October 1988. Mr. Jiang’s contribution to the TCM sector has been recognized with prestigious awards, including the “First Prize of Sichuan Science and Technology Progress Award” (四川省科學技術進步獎一等獎) by the Sichuan Provincial People’s Government in April 2016, and the “Second Prize of Science and Technology Award of the Chinese Society of Traditional Chinese Medicine” (中華中醫藥學會科學技術獎二等獎) by the Chinese Society of Traditional Chinese Medicine in November 2020.

Mr. Feng Bin (馮斌), aged 62, is an executive Director and the general manager of our Company. He was appointed as a Director and general manager of our Company in May 2009 and was redesignated as an executive Director on March 26, 2025. In addition to these roles, Mr. Feng currently holds directorships at two subsidiaries within our Group. Mr. Feng is mainly responsible for the overall corporate and business strategies and key business and operational decision-making of our Group.

Joining our Group in May 2003, Mr. Feng ascended through various strategic roles, including the sales manager and the deputy general manager of sales, steering our Company through numerous successful initiatives and growth phases.

Mr. Feng obtained a bachelor’s degree in textile engineering from Northwest Textile Science and Technology University (西北紡織工學院) (currently known as Xi’an Polytechnic University (西安工程大學)) in China in July 1983.

Mr. Jiang Ercheng (江爾成), aged 35, is an executive Director and the deputy director of R&D of our Company. Mr. Jiang Ercheng was appointed as a Director in February 2019 and was redesignated as an executive Director on March 26, 2025. He is primarily responsible for the overall strategic planning and development of our Group.

Mr. Jiang Ercheng brings to our Group global strategic insights and management experience in the biopharmaceutical industry. His professional endeavors began with the position as the general manager at Kinna Investment from September 2013 to April 2022, where he was instrumental in navigating the company through complex investment decisions and growth strategies. Further solidifying his strategic planning capabilities, Mr. Jiang Ercheng served as a non-executive director at Pharmesis International from July 2016 to November 2017, being pivotal in the company’s direction on an international scale.

Mr. Jiang Ercheng obtained a bachelor’s degree in biochemistry from the University of California in the United States in June 2013 and a master’s degree in environmental and public health management from Hong Kong Baptist University in May 2023.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Luo Yujin (羅玉金), aged 43, is an executive Director and the deputy general manager of our Company. Mr. Luo was appointed as a Director in February 2019 and was redesignated as an executive Director on March 26, 2025. He is primarily responsible for the overall management of sales center of our Group.

Joining our Group in September 2003, Mr. Luo has cultivated a rich trajectory of growth through dedicated service and a strategic mindset, and successively served as the logistics supervisor from September 2003 to December 2008, sales manager from January 2009 to December 2014 and sales director from January 2015 to December 2015.

Mr. Luo graduated in meteorology from Hunan Hengyang Adult Secondary Specialized School (湖南省衡陽市成人中等專業學校) in China in July 2002.

Mr. Lan Zelun (蘭澤倫), aged 43, is an executive Director and the secretary of the Board of our Company. Mr. Lan was appointed as a Director in February 2025 and was redesignated as an executive Director on March 26, 2025. He is primarily responsible for information disclosure and investor relations management, equity affairs management and corporate governance.

Mr. Lan joined our Group in July 2007 and held several management positions within the R&D department. He was promoted to the position of secretary of the Board in July 2023.

Mr. Lan obtained a bachelor’s degree in Chinese medicinal science and a master’s degree in pharmacognosy from Chengdu University of Traditional Chinese Medicine (成都中醫藥大學) in China in July 2004 and in June 2007, respectively. In March 2023, Mr. Lan was also awarded the “Third Prize of Sichuan Provincial Science and Technology Progress Award” (四川省科學技術進步獎三等獎) by the People’s Government of Sichuan Province.

Non-executive Director

Mr. Lai Zhitian (賴智填), aged 57, is a non-executive Director of our Company. Mr. Lai was appointed as a Director in August 2023 and was redesignated as a non-executive Director on March 26, 2025. He is mainly responsible for overseeing Board affairs and giving strategic advice and guidance on the business operations of our Group.

Mr. Lai has over 30 years of experience in the pharmaceutical industry and has extensive experience in pharmaceutical products development, manufacturing and distribution. Mr. Lai is the ultimate controller of Zhongshan Pharmaceutical Management Company (中山市醫藥經營公司) (currently known as Zhongshan Zhongzhi Pharmaceutical Group Co. Ltd (中山市中智藥業集團有限公司)) (“**Zhongzhi Pharmaceutical**”), one of the Pre-[REDACTED] Investors, and currently serves as: (i) the general manager, and (ii) the chairman and director of Zhongzhi Pharmaceutical. Zhongzhi Pharmaceutical is an indirect wholly owned subsidiary of Zhongzhi Pharmaceutical Holdings Limited (中智藥業控股有限公司), a company principally engaged in pharmaceutical manufacturing and the operation of chain pharmacies, whose shares are listed on the Stock Exchange (stock code: 3737), where he has been serving as its chairman and executive director since January 2015 and is responsible for the operation and management of the company.

Mr. Lai holds, amongst others, the following positions: (i) associate professor and master’s course instructor of the Research Center of Chinese Herbal Resource Science and Engineering in Guangzhou University of Chinese Medicine (廣州中醫藥大學中藥資源科學與工程研究中心); and (ii) executive vice chairman of Guangdong Association of Traditional Chinese Medicine (廣東省中藥協會).

Independent Non-executive Directors

Dr. Wan Jianbo (萬建波), aged 45, is an independent non-executive Director of our Company. Dr. Wan was appointed as an independent Director in October 2023 and was redesignated as an independent non-executive Director on March 26, 2025. He is mainly responsible for providing independent advice and judgment to our Board.

DIRECTORS AND SENIOR MANAGEMENT

Dr. Wan brings a wealth of academic expertise to his role. He has had a prolific academic career at the University of Macau (澳門大學), where he initially joined as an assistant professor in August 2011, advanced to an associate professor in August 2017 and has been serving as a professor since August 2023.

Dr. Wan obtained a bachelor’s degree in pharmacy from Wuhan University (武漢大學) in China in June 2001, and a master’s degree in pharmaceutical chemistry from China Pharmaceutical University (中國藥科大學) in China in June 2004, as well as a master’s degree in traditional Chinese medicine from the University of Macau (澳門大學) in Macau in August 2004. Further, Dr. Wan obtained a Ph.D. in biomedicine from the University of Macau (澳門大學) in Macau in August 2008. Following his Ph.D., Dr. Wan completed a postdoctoral fellowship at the Laboratory of Lipid Medicine and Technology, Massachusetts General Hospital & Harvard Medical School in the United States in April 2011.

Dr. Chen Jianping (陳建萍), aged 68, is an independent non-executive Director of our Company. Dr. Chen was appointed as an independent Director in February 2025 and was redesignated as an independent non-executive Director on March 26, 2025. She is mainly responsible for the providing independent advice and judgment to our Board.

Dr. Chen boasts an illustrious career spanning over three decades in the field of TCM, marked by academic leadership, clinical excellence, and groundbreaking research. From July 1984 to August 1993, she successively trained as resident physician and attending physician. From July 1998 to October 2000, she served as an associate professor of Sun Yat-sen Medical University (中山醫科大學) (currently merged into Sun Yat-sen University (中山大學)) focusing on TCM researches. Later in 2001, Dr. Chen joined The University of Hong Kong as an assistant professor at the TCM division of School of Professional and Continuing Education. She further transitioned to School of Chinese Medicine of The University of Hong Kong in 2002 and successively served as its assistant professor and associate professor. Starting from September 2020, she has been a principal lecturer of School of Chinese Medicine.

Dr. Chen obtained a bachelor’s degree, a master’s degree and a Ph.D., all in traditional Chinese medicine, from Chengdu College of Traditional Chinese Medicine (成都中醫學院) (currently known as Chengdu University of Traditional Chinese Medicine (成都中醫藥大學)) in July 1984, July 1990 and July 1996, respectively.

Ms. Liu Jianhua (劉建華), aged 56, is an independent non-executive Director of our Company. Ms. Liu was appointed as an independent non-executive Director on March 26, 2025. She is mainly responsible for the providing independent advice and judgment to our Board.

Ms. Liu possesses over 25 years of profound expertise in financial management and professional advisory services. She has been serving as the chairperson of Sichuan Hongyu Jianhua Tax & Financial Advisory Co., Ltd. (四川宏宇建華財稅諮詢有限公司) since June 2024, and the general manager of Sichuan BetterLink Accounting Firm Co., Ltd. (四川貝特領勢會計師事務所有限公司) since September 2017.

Ms. Liu obtained her diploma in accounting from China Central Radio and TV University (中央廣播電視大學) (currently known as The Open University of China (國家開放大學)) in January 2009. She further obtained a master’s degree in business administration from Hong Kong Finance and Economics College in September 2016. Ms. Liu also holds membership at the Chinese Institute of Certified Public Accountants (中國註冊會計師協會).

SENIOR MANAGEMENT

Our senior management is responsible for the day-to-day management of our business. The following table sets forth the key information about our senior management as of the Latest Practicable Date.

DIRECTORS AND SENIOR MANAGEMENT

Name	Age	Positions	Roles and responsibilities	Date of joining our Group	Date of appointment as a senior management
Mr. Feng Bin (馮斌)	62	Executive Director and general manager	Overall corporate and business strategies and key business and operational decision-making of our Group	May 10, 2003	May 10, 2009
Mr. Luo Yujin (羅玉金)	43	Executive Director and deputy general manager	Overall management of sales center of our Group	September 12, 2003	April 1, 2017
Mr. Lan Zelun (蘭澤倫)	43	Executive Director and secretary of the Board	Information disclosure and investor relations management, equity affairs management and corporate governance	July 3, 2007	July 28, 2023
Ms. Zhang Xiaojia (張曉佳)	51	Deputy general manager	Overall management of the production management center	October 2008	March 18, 2022
Mr. Liao Min (廖敏)	38	Finance director	Overall financial management and planning of our Group	May 13, 2014	July 28, 2023

Mr. Feng Bin (馮斌), aged 62, is the general manager of our Company. For his biography, see “— Board of Directors — Executive Directors” in this section.

Mr. Luo Yujin (羅玉金), aged 43, is a deputy general manager of our Company. For his biography, see “— Board of Directors — Executive Directors” in this section.

Mr. Lan Zelun (蘭澤倫), aged 43, is the secretary of the Board of our Company. For his biography, see “— Board of Directors — Executive Directors” in this section.

Ms. Zhang Xiaojia (張曉佳), aged 51, was appointed as a deputy general manager of our Company in March 2022. Apart from these roles, Ms. Zhang currently holds directorship at one subsidiary within our Group. She is mainly responsible for the overall management of the production management center.

Ms. Zhang joined our Group in November 2008, initially serving as the administration manager. She then advanced to the role of administration and human resources director in January 2013, before being promoted to deputy general manager in March 2022.

Ms. Zhang obtained her diploma in accounting from Chengdu Institute of Meteorology (成都氣象學院) (currently known as Chengdu University of Information Technology (成都資訊工程大學)) in China in June 1997 and a master’s degree in business administration from the Capital University of Economics and Business (首都經濟貿易大學) in China in January 2003.

Mr. Liao Min (廖敏), aged 38, was appointed as finance director of our Company in July 2023. He is mainly responsible for overall financial management and planning of our Group.

Mr. Liao joined our Group in May 2014, initially serving as a finance specialist. He then advanced to deputy finance manager and finance executive manager, before being promoted to financial director in July 2023.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Liao obtained a bachelor’s degree in accounting from Jiangxi Science and Technology Normal College (江西科技師範學院) (currently known as Jiangxi Science and Technology Normal University (江西科技師範大學)) in China in July 2010.

OTHER INFORMATION IN RELATION TO OUR DIRECTORS AND SENIOR MANAGEMENT

Save as disclosed above, to the best knowledge, information and belief of the Directors having made all reasonable inquiries, there are no material matters relating to their appointment as a Director that need to be brought to the attention of our Shareholders and there is no other information in relation to his or her appointment which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and paragraph 2 of chapter 3.10 of the Guide for New Listing Applicants as of the Latest Practicable Date.

Save as disclosed above, none of the Directors and senior management held any other directorships in any other company [REDACTED] in Hong Kong or overseas during the three years immediately preceding the date of this document.

Save as disclosed above, none of our Directors and senior management is related to other Directors and senior management.

JOINT COMPANY SECRETARIES

Mr. Lan Zelun (蘭澤倫) was appointed as one of the joint company secretaries of our Company with effect from [REDACTED]. For details of his biography, see “— Board of Directors — Executive Directors” above.

Mr. Poon Kin Hei (潘健希) was appointed as one of our joint company secretaries with effect from [REDACTED].

Mr. Poon currently serves as a manager of the corporate secretarial department of TMF Hong Kong Limited and is responsible for the provision of corporate secretarial and compliance services to public company clients. He had over 10 years of experience in the company secretarial field. Mr. Poon is an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators) in the United Kingdom.

Mr. Poon obtained a bachelor’s degree in engineering from The Chinese University of Hong Kong in December 2002 and a master of science in professional accounting and corporate governance (CG Stream) from the City University of Hong Kong in July 2011.

BOARD COMMITTEES

Our Company has established four committees under the Board in accordance with the relevant laws and regulations in Chinese Mainland, the Articles and the code of corporate governance practices under the Listing Rules, including the Audit Committee, the Remuneration and Appraisal Committee, the Nomination Committee and the Strategy Committee.

Audit Committee

We have established the Audit Committee in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal control system of our Group, review and approve connected transactions and to advise the Board. The Audit Committee comprises one non-executive Director and two independent non-executive Directors, namely, Ms. Liu Jianhua, Dr. Wan Jianbo and Mr. Lai Zhitian. Ms. Liu Jianhua is the chairperson of the Audit Committee. She holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules.

DIRECTORS AND SENIOR MANAGEMENT

Remuneration and Appraisal Committee

We have established the Remuneration and Appraisal Committee in compliance with Rule 3.25 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The primary duties of the Remuneration and Appraisal Committee are to review and make recommendations to the Board regarding the terms of remuneration packages, bonuses and other compensation payable to our Directors and senior management. The Remuneration and Appraisal Committee comprises one executive Director and two independent non-executive Directors, namely, Dr. Wan Jianbo, Ms. Liu Jianhua and Mr. Feng Bin. Dr. Wan Jianbo is the chairperson of the Remuneration and Appraisal Committee.

Nomination Committee

We have established the Nomination Committee in compliance with the Code on Corporate Governance set out in Appendix C1 to the Listing Rules. The primary duties of the Nomination Committee are to make recommendations to our Board regarding the appointment of Directors and Board succession. The Nomination Committee comprises one executive Director and two independent non-executive Directors, namely, Mr. Jiang Yun, Dr. Wan Jianbo and Dr. Chen Jianping. Mr. Jiang Yun is the chairperson of the Nomination Committee.

Strategy Committee

We have established the Strategy Committee in compliance with the Article of Association. The primary duties of the Strategy Committee are to make recommendations to our Board on the long-term development strategy and major investments and projects of our Company. The Strategy Committee comprises one executive Director, one non-executive Director and one independent non-executive Director, namely Mr. Jiang Yun, Mr. Lai Zhitian and Dr. Wan Jianbo. Mr. Jiang Yun is the chairperson of the Strategy Committee.

CORPORATE GOVERNANCE CODE

We recognize the importance of incorporating elements of good corporate governance in our management structure and internal control procedures so as to achieve effective accountability. We have adopted the code provisions stated in the Corporate Governance Code. We are committed to the view that the Board should include a balanced composition of executive Directors, non-executive Directors and independent non-executive Directors so that there is a strong independent element on the Board that can effectively exercise independent judgment.

To accomplish the high standards of corporate governance, we will comply with the Corporate Governance Code set out in Appendix C1 to the Listing Rules and the associated Listing Rules after the [REDACTED].

MANAGEMENT PRESENCE

According to Rules 8.12 and 19A.15 of the Listing Rules, we must have sufficient management presence in Hong Kong. This normally means that at least two of our executive Directors must be ordinarily resident in Hong Kong. Since the principal business operations of our Group are conducted in Chinese Mainland, members of our senior management are, and are expected to continue to be, based in Chinese Mainland. Further, as our executive Directors have a vital role in our Group’s operations, it is crucial for them to remain in close proximity to our Group’s central management located in Chinese Mainland. Our Company does not and, for the foreseeable future, will not have a sufficient management presence in Hong Kong. We have applied for, and the Stock Exchange [has granted], a waiver from compliance with Rules 8.12 and 19A.15 of the Listing Rules. For further details, see “Waivers from Strict Compliance with the Listing Rules — Management Presence in Hong Kong.”

DIRECTORS AND SENIOR MANAGEMENT

BOARD DIVERSITY POLICY

Our Board has adopted a diversity policy to support our strategic goals and sustainable growth. We value diversity in areas such as gender, age, background, experience, and skills. Director candidates are selected based on merit and their alignment with our business needs, with diversity as an important consideration. We place particular emphasis on gender diversity. After the [REDACTED], we aim to gradually increase the number of female directors by identifying and maintaining a pool of qualified female candidates with diverse expertise. Female investor representatives are also considered, and we promote gender balance in mid-to senior-level recruitment to build a pipeline of future female leaders. We will provide training to high-potential female employees in areas such as operations, management, finance, and compliance, to prepare them for leadership roles. Our Nomination Committee oversees board diversity and will review the policy annually. Progress and measurable outcomes will be disclosed in our corporate governance report.

COMPLIANCE ADVISOR

We have appointed First Shanghai Capital Limited as our Compliance Advisor pursuant to Rule 3A.19 of the Listing Rules. Our Compliance Advisor will provide us with guidance and advice as to compliance with the Listing Rules and applicable Hong Kong laws. Pursuant to Rule 3A.23 of the Listing Rules, our Compliance Advisor will advise our Company in certain circumstances including:

- (i) before the publication of any regulatory announcement, circular, or financial report;
- (ii) where a transaction, which might be a notifiable or connected transaction, is contemplated, including share issues, sales or transfers of treasury shares and share repurchases; and
- (iii) where we propose to [REDACTED] of the [REDACTED] in a manner different from that detailed in this document or where the business activities, development or results of our Group deviate from any forecast, estimate or other information in this document; and where the Stock Exchange makes an inquiry to our Company regarding unusual movements in the [REDACTED] or [REDACTED] of its [REDACTED] securities or any other matters in accordance with Rule 13.10 of the Listing Rules.

Pursuant to Rule 3A.24 of the Listing Rules, the Compliance Advisor will, on a timely basis, inform our Company of any amendment or supplement to the Listing Rules that are announced by the Stock Exchange. The Compliance Advisor will also inform our Company of any new or amended law, regulation or code in Hong Kong applicable to us, and advise us on the applicable requirements under the Listing Rules and laws and regulations.

The term of appointment of our Compliance Advisor shall commence on the [REDACTED] and is expected to end on the date on which we comply with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the [REDACTED].

REMUNERATION OF DIRECTORS AND FIVE HIGHEST PAID INDIVIDUALS

The Directors and senior management members who receive remuneration from the Company are paid in forms of wages, salaries, bonuses and pension scheme contributions. When reviewing and determining the specific remuneration packages for our Directors and members of the senior management of our Company, the Shareholders’ meetings and the Board of Directors take into account factors such as salaries paid by comparable companies, time commitment, level of responsibilities, employment elsewhere in our Group and desirability of performance-based remuneration. As required by the relevant PRC laws and regulations, our Company also participates in various defined contribution plans organized by relevant provincial and municipal government authorities and welfare schemes for employees of our Company, including medical insurance, injury insurance, unemployment insurance, pension insurance, maternity insurance and housing provident fund.

DIRECTORS AND SENIOR MANAGEMENT

For the years ended December 31, 2023, 2024 and 2025, the total amount of remuneration (including fees, wages, salaries, bonuses and pension scheme contributions) and other benefits in kind (if applicable) paid to our Directors were RMB4.2 million, RMB2.7 million and RMB3.6 million, respectively.

According to existing effective arrangements, we estimate the total remuneration before taxation to be accrued to our Directors in kind for their service for the year ending December 31, 2026 to be approximately RMB4.0 million. The actual remuneration of our Directors in 2026 may be different from the expected remuneration.

For the years ended December 31, 2023, 2024 and 2025, the total emoluments paid to the five highest paid individuals (excluding two, two and three Directors) amounted to RMB2.8 million, RMB2.5 million and RMB1.5 million, respectively.

During the Track Record Period, no remuneration was paid by our Company to, or receivable by, our Directors or the five highest paid individuals as an inducement to join or upon joining our Company or as compensation for loss of office in connection with the management positions of our Company or any of our subsidiaries.

During the Track Record Period, none of our Directors waived any remuneration. Save as disclosed above, during the Track Record Period, no other amounts shall be paid or payable by us or any of our subsidiaries to our Directors or the five highest paid individuals.

CONFIRMATIONS FROM OUR DIRECTORS

Rule 8.10 of the Listing Rules

Each of our Directors confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, directly or indirectly, with our business and requires disclosure under Rule 8.10 of the Listing Rules.

From time to time our non-executive Director, namely Mr. Lai Zhitian, may serve on the boards of both private and public companies within the broader healthcare and biopharmaceutical industries. However, as Mr. Lai is not member of our executive management team, we do not believe that Mr. Lai’s interests in such companies as director would render us incapable of carrying on our business independently from the other companies in which Mr. Lai may hold directorships from time to time.

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on March 29, 2025, and (ii) understands his or her obligations as a director of a [REDACTED] issuer under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his or her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) he or she have no past or present financial or other interest in the business of our Company or its subsidiaries or any connection with any core connected person of our Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his or her independence at the time of his or her appointments.